Levera Solution contains Levetiracetam 100 mg/ml, an antiepileptic agent indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam’s mechanism of action is believed to involve modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levera is administered orally and is rapidly absorbed, achieving peak plasma concentrations within one hour, with linear pharmacokinetics and minimal protein binding. It is primarily eliminated unchanged via renal excretion, necessitating dose adjustments in patients with impaired renal function. Levera Solution is well tolerated, with common adverse effects including somnolence, dizziness, headache, and fatigue; serious adverse reactions are rare but may include behavioral changes such as irritability or depression. This medication should be used under medical supervision, with careful monitoring for efficacy and tolerability, especially during initiation and dose escalation. Levera Solution offers a convenient liquid formulation, suitable for patients who have difficulty swallowing tablets, including pediatric and geriatric populations. It should be stored at controlled room temperature and protected from light. Use during pregnancy and lactation requires risk-benefit assessment by the prescribing physician.